0001209191-24-004385.txt : 20240305 0001209191-24-004385.hdr.sgml : 20240305 20240305165853 ACCESSION NUMBER: 0001209191-24-004385 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Powell Andrew Kenneth William CENTRAL INDEX KEY: 0001304113 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 24721866 MAIL ADDRESS: STREET 1: C/O COLLAGENEX PHARMACEUTICALS, INC. STREET 2: 41 UNIVERSITY DRIVE CITY: NEWTOWN STATE: PA ZIP: 18940 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 701 LEE ROAD STREET 2: SUITE 103 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2024-03-01 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001304113 Powell Andrew Kenneth William C/O ACLARIS THERAPEUTICS, INC. 701 LEE ROAD, SUITE 103 WAYNE PA 19087 1 0 0 0 0 Common Stock 2024-03-01 4 P 0 8500 1.23 A 22863 D Common Stock 2024-03-04 4 P 0 6000 1.25 A 28863 D The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.2393, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $1.230 to $1.269, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. /s/ Mark Ballantyne, Attorney-in-Fact 2024-03-05